{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:58:38Z","timestamp":1762865918870,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jacl.2011.11.007","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T17:21:58Z","timestamp":1323364918000},"page":"180-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects\u00a0on low-density lipoprotein-cholesterol reduction"],"prefix":"10.1016","volume":"6","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena Rosen","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Neff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. Henry","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaan","family":"Tunceli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.11.007_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.11.007_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expt Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2011.11.007_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe\u00a0+ statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.11.007_bib4","unstructured":"Vytorin [product insert]. N. Wales, PA: Merck\/Schering-Plough Pharmaceuticals; 2010."},{"key":"10.1016\/j.jacl.2011.11.007_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib6","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib7","unstructured":"Carotid atorvastatin study in hyperlipidemia post-menopausal women: a randomized evaluation of atorvastatin versus placebo (Cashmere). NCT#00163163. Pfizer PhRMA Web Synopsis Protocol A2581051. Final Report. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00163163. Accessed December 7, 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.007_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacl.2008.06.011","article-title":"Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: should ezetimibe move to the \u201cback of the line\u201d as a therapy for dyslipidemia?","volume":"2","author":"Toth","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.11.007_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3949\/ccjm.75.7.479","article-title":"Is ezetimibe\/simvastatin no better than simvastatin alone? Lessons learned and clinical implications","volume":"75","author":"Davidson","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib11","unstructured":"Crestor (rosuvastatin calcium) tablets [package insert]. Wilmington, DE: AstraZeneca; 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib12","unstructured":"Lescol\/Lescol XL (fluvastatin) [package insert]. E. Hanover, NJ: Novartis Pharmaceuticals Corp.; 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib13","unstructured":"Pravachol [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib14","unstructured":"Zocor (simvastatin) tablets [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2010."},{"key":"10.1016\/j.jacl.2011.11.007_bib15","unstructured":"Mevacor [product insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2010."},{"key":"10.1016\/j.jacl.2011.11.007_bib16","unstructured":"Zetia [product insert]. N. Wales, PA: Merck\/Schering-Plough Pharmaceuticals; 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib17","unstructured":"Lipitor (atorvastatin calcium) tablets [package insert]. New York, NY: Parke-Davis; 2009."},{"key":"10.1016\/j.jacl.2011.11.007_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMe0801842","article-title":"Cholesterol lowering and ezetimibe","volume":"358","author":"Drazen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMe0801608","article-title":"Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?","volume":"358","author":"Brown","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib20","unstructured":"U.S. Food and Drug Administration. Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe\/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor). January 8, 2009. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm079524.htm. Accessed December 7, 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib21","unstructured":"American Heart Association. Statement from the American Heart Association on ENHANCE study results. 2008. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm079524.htm."},{"key":"10.1016\/j.jacl.2011.11.007_bib22","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.11.007_bib23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0091270009337011","article-title":"The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study","volume":"49","author":"Meaney","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2011.11.007_bib24","unstructured":"National Institutes of Health. NIH stops clinical trial on combination cholesterol treatment. Available at: http:\/\/www.nih.gov\/news\/health\/may2011\/nhlbi-26.htm. Accessed December 7, 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib25","unstructured":"National Heart Lung, and Blood Institute. Niacin Plus Statin to Prevent Vascular Events. 2005. Available at: http:\/\/clinicaltrials.gov\/show\/NCT00120289. Accessed December 7, 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/14779072.6.6.781","article-title":"Is it over for ezetimibe?","volume":"6","author":"Robinson","year":"2008","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2011.11.007_bib27","unstructured":"University of Oxford. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00461630. Accessed December 7, 2011."},{"key":"10.1016\/j.jacl.2011.11.007_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.11.007_bib29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib31","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2165\/10898610-000000000-00000","article-title":"Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs","volume":"70","author":"Toth","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2011.11.007_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2010.10.004","article-title":"Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease\/coronary heart disease-equivalent patients","volume":"4","author":"Tunceli","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.11.007_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MJT.0b013e3181b442b9","article-title":"Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol","volume":"17","author":"Aronow","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.jacl.2011.11.007_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/07853890902729786","article-title":"Clinical review: impact of statin substitution policies on patient outcomes","volume":"41","author":"Atar","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2011.11.007_bib36","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2011.11.007_bib37","first-page":"601","article-title":"Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses","volume":"16","author":"Briel","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2011.11.007_bib38","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2011.11.007_bib39","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1185\/030079907X210507","article-title":"Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy","volume":"23","author":"Mikhailidis","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2011.11.007_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","article-title":"Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis","volume":"27","author":"Mikhailidis","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2011.11.007_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2010.03.004","article-title":"An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design","volume":"159","author":"Califf","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2011.11.007_bib42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of Ezetimibe\/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2011.11.007_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetmibie in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2011.11.007_bib44","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.007_bib45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.amjcard.2010.01.363","article-title":"Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial","volume":"105","author":"Holme","year":"2010","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411008294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411008294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:02Z","timestamp":1761831182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411008294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1933287411008294"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.11.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects\u00a0on low-density lipoprotein-cholesterol reduction","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2011.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}